The effectiveness of recombinant human erythropoietin (r-HuEpo)
Abstract
The effectiveness of recombinant human erythropoietin (r-HuEpo) in raising haemoglobin concentrations in very low birthweight infants was examined in a randomised multicentre study. Twenty nine 'healthy' appropriate for gestational age infants with birth weights 900-1400 g entered the study at 3 weeks of age. All infants received breast milk supplemented with 9 g/l human breast milk protein from 3 to 8 weeks of age. Eighteen mg iron was given daily from week 3 and was doubled if serum iron concentration fell below 16*0 ,umolIl. Fourteen infants were randomised to receive 100 U/kg r-HuEpo subcutaneously three times a week from week 3 to week 7; 15 infants served as controls.
After one week reticulocyte and haemoglobin concentrations were significantly higher in the r-HuEpo treated group and the haemoglobin values remained significantly higher throughout r-HuEpo treatment and at the concentrations observed in full term infants. No adverse effects were associated with the treatment.
In stable very low birthweight infants with optimal iron and protein intakes, moderate dose r-HuEpo can produce significant gains in red cell production that may be clinically usefil.
(Arch Dis Child 1993; 69: [19] [20] [21] [22] [23] Hitherto, blood transfusion has been the chief means of correcting anaemia in preterm infants. Blood transfusion has small, but significant risks and thus any measures that could increase the infant's own production of erythrocytes and reduce the need for transfusion would be welcome.
Haemoglobin concentrations decrease in all infants during the first few months after birth and this is termed the physiological anaemia of infancy. In preterm infants the fall in haemoglobin is greater and more rapid, reaching a nadir at [5] [6] [7] [8] When planning the present study on r-HuEpo treatment of preterm infants, we considered three observations to be particularly pertinent:
(1) Human milk protein supplementation alleviates the early anaemia in preterm infants fed human milk, suggesting that the available supply of protein provided by ordinary breast milk is insufficient for red cell production during this period of very rapid growth. 14 (2) The early anaemia in rabbits, mice, and pigs is completely abolished by plentiful supplies of iron, indicating that sufficient 'available iron' is essential for increased erythropoiesis during rapid growth. 15 The infants were randomised separately at each centre to receive r-HuEpo treatment or serve as controls. Randomisation was performed by prenumbered sealed envelopes.
Written informed consent was obtained from the parents in all cases. The study was approved by the regional ethics committee.
METHODS
The study period lasted from 3 to 8 weeks of age with an additional assessment at 16 weeks.
Treatment andfeeding regimen
The r-HuEpo (Eprex, Cilag, 2000 U/ml) was given subcutaneously in a dose of 100 U/kg three times a week from 3 to 7 weeks of age.
All infants received 170-180 ml/kg/day of human milk from either their mothers or the milk bank. The milk was fortified from week 3 to week 8 with pasteurised, freeze dried human milk protein in the amount of 9 g/l in accordance with Ronnholm and Siimes.14 Total protein intake was approximately 3-0 g/kg/day.
Oral iron supplementation, 18 mg iron/day regardless of weight, given as iron fumarate (Neo-Fer, Nyco), was commenced at the start of the study (3 weeks of age). If serum iron concentration fell below 1 6X0 ,umoI/l (90 ,ug/100 ml), the dose was increased to 36 mg iron/day. At the end of the study period (8 Results were very close to those obtained for the complete data set.
Results
The table shows the pretreatment characteristics. The treatment and control groups were similar with respect to birth weight, gestational age, sex ratio, weight at entry, and baseline haematological values. Reticulocytes, both in percentage ofred cells and in absolute numbers, increased rapidly and significantly (p<0-0001) after one week of r-HuEpo treatment (fig 1) . Significant treatment effects on reticulocyte values were found after one, two, and three weeks of treatment. In the control group the reticulocyte counts showed the normal rise and were significantly higher at 4 to 8 weeks of life compared with initial values (p<0 01) (fig 1) . During the last week of r-HuEpo treatment (6 to 7 weeks of age) there was a small decline in reticulocyte count (p<0 05), but a highly significant fall was observed after the cessation of r-HuEpo treatment at 7 weeks of age (p-<0000 1). Figure 2 displays the haemoglobin and packed cell volume values. The treatment effect was already significant after one week (age 4 weeks), and this effect was sustained throughout the treatment period. The lowest mean haemoglobin concentration in the r-HuEpo group was 112 g/l at 5 weeks of age while that of the controls was 98 g/l (week 7). The red cell indices were similar in both groups throughout the study.
All but three infants (two r-HuEpo treated, one control) required an increase in iron dosage due to serum iron concentration less than 16-0 ,umol/l. Serum iron fell initially in the r-HuEpo treated group. After one week of treatment they had significantly lower values than the controls (14 ,umoll v 19 pumoIl). Thereafter the concentrations were equivalent. Serum ferritin concentrations displayed the expected fall in both groups,21 and there were no significant differences between them. During the study period four infants in the control group were transfused with red blood cells, none in the r-HuEpo group.
There were no significant differences between the groups in total white blood cell and neutrophil counts. No case of neutropenia (neutrophils <109/1) was observed during the r-HuEpo treatment. One control infant had neutropenia at age 7 and 8 weeks. One r-HuEpo treated infant had 09X I09/1 neutrophils at age 16 weeks, that is nine weeks after the last r-HuEpo injection. Platelet counts increased slightly during the study period in both groups with no significant differences between them.
Growth (weight, length, and head circumference) was similar in the two groups with a weight gain of about 200 g/week, nearly corresponding to the in utero increments. 19 No adverse effects were observed during the study. In particular, no hypertension or differences in blood pressure between the groups were encountered. There were no reactions to the injections, the oral iron, or the protein supplementation. All biochemical indices were within normal range. One patient in the control group was withdrawn from the study due to suspected, but at no time verified, septicaemia. His serum iron concentrations were within the normal range (at withdrawal: 147 jxmoJl).
Discussion
In this randomised trial we have clear evidence that small preterm infants are able to respond to exogenous erythropoietin with increased erythropoiesis. The response was already seen after one week of r-HuEpo treatment in reticulocyte count as well as haemoglobin and packed cell volume values (figs 1 and 2). The nadir of haemoglobin concentration in the r-HuEpo treated group was 112 g/l. This value is similar to the nadir observed in full term infants.22 23 Thus the r-HuEpo treatment abolished the early anaemia of prematurity in these infants.
A point of interest is the drop observed in reticulocyte counts during the last week of r-HuEpo treatment and the first week after cessation of treatment at 7 weeks of age. The cause of this possible decline in erythropoiesis during and shortly after stopping r-HuEpo treatment might be that the endogenous 
Why did we obtain such a clear cut r-HuEpo response with moderate doses while others have failed to do so?8 9We believe that the protein and iron supplements given to the infants in our study constitute the major explanation. Ronnholm and Siimes found that human milk protein supplementation ameliorates the early anaemia in preterms fed human milk. 14 In the present investigation we provided the same kind of protein supplement in the same amount to both the r-HuEpo group and the controls during the study period. Our objective in this respect was to supply sufficient protein both for the increased erythropoiesis that r-HuEpo treatment could cause, and to ensure enough protein for the rapid growth of the preterm infant at this age. We were concerned that the artificial hormone stimulation could divert protein needed for essential growth or other organs into red cell production if a deficiency or marginal provision of available protein occurred.
Functional iron deficiency during r-HuEpo treatment of older subjects has been frequently reported. 24 Neutropenia, suggested as side effect of r-HuEpo treatment in preterm infants,7 10 was not observed in our study. In the uncontrolled pilot study of Halperin et al thrombocytosis as a side effect was postulated. 7 We observed no differences between the groups in our study, and a rise in platelet count appears to be a normal phenomenon in preterm infants. 27 The present study is too limited to answer whether all preterms would benefit from r-HuEpo treatment. Our aim was to establish whether the preterm infant is able to respond to exogenous erythropoietin with increased red cell production during the time of the early anaemia. We chose a selected group to answer this: healthy, orally fed, well nourished infants with birth weights 900-1400 g and appropriate for gestational age who were studied at 3-8 weeks of age. The marked increase in red cell production we have demonstrated, however, may be of significant clinical value and reduce the need for transfusion. It remains to be seen whether smaller and sick infants respond to r-HuEpo in the same fashion, as well as how early after birth treatment can be effective. The need for securing adequate nutrition (iron, protein, and perhaps other essentials) might in such infants be even more crucial.
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